Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Drug Details

Click here to go back to your search results.

Brand Name: Matulane Trade Name: procarbazine
FDA Approved For: Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. Pediatric Use: Very close clinical monitoring is mandatory. Undue toxicity, evidenced by tremors, coma and convulsions, has occurred in a few cases. Dosage, therefore, should be individualized.
Carcinogen: The carcinogenicity of procarbazine hydrochloride in mice, rats and monkeys has been reported in a considerable number of studies. Instances of a second nonlymphoid malignancy, including acute myelocytic leukemia, have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation. The International Agency for Research on Cancer (IARC) considers that there is "sufficient evidence" for the human carcinogenicity of procarbazine hydrochloride when it is given in intensive regimens which include other antineoplastic agents but that there is inadequate evidence of carcinogenicity in humans given procarbazine hydrochloride alone. Mutagen: Procarbazine hydrochloride has been shown to be mutagenic in a variety of bacterial and mammalian test systems.
Manufacturer and/or Distributor: Sigma Tau Pharms    

Adverse Reactions:
Leukopenia, anemia and thrombopenia occur frequently. Nausea and vomiting are the most commonly reported side effects. Other adverse reactions are: Hematologic: Pancytopenia; eosinophilia; hemolytic anemia; bleeding tendencies such as petechiae, purpura, epistaxis and hemoptysis. Gastrointestinal: Hepatic dysfunction, jaundice, stomatitis, hematemesis, melena, diarrhea, dysphagia, anorexia, abdominal pain, constipation, dry mouth. Neurologic: Coma, convulsions, neuropathy, ataxia, paresthesia, nystagmus, diminished reflexes, falling, foot drop, headache, dizziness, unsteadiness. Cardiovascular: Hypotension, tachycardia, syncope. Ophthalmic: Retinal hemorrhage, papilledema, photophobia, diplopia, inability to focus. Respiratory: Pneumonitis, pleural effusion, cough. Dermatologic: Herpes, dermatitis, pruritus, alopecia, hyperpigmentation, rash, urticaria, flushing. Allergic: Generalized allergic reactions. Genitourinary: Hematuria, urinary frequency, nocturia. Musculoskeletal: Pain, including myalgia and arthralgia; tremors. Psychiatric: Hallucinations, depression, apprehension, nervousness, confusion, nightmares. Endocrine: Gynecomastia in prepubertal and early pubertal boys. Miscellaneous: Intercurrent infections, hearing loss, pyrexia, diaphoresis, lethargy, weakness, fatigue, edema, chills, insomnia, slurred speech, hoarseness, drowsiness. Second nonlymphoid malignancies, including acute myelocytic leukemia and malignant myelosclerosis, and azoospermia have been reported in patients with Hodgkin's disease treated with procarbazine in combination with other chemotherapy and/or radiation.


E-mail to a Friend More Information

 

Disclaimer:This site provides excerpts from the product label or professional information brochures for some drugs or information provided by the World Health Organization’s International Agency for Research on Cancer. The full information from these sources is not provided by CancerMonthly. To view the full label or professional information brochure please contact the FDA. A link to the product label or professional information brochure is provided for your convenience, but CancerMonthly is not responsible for the availability of such external sites or resources. In addition, CancerMonthly does not provide medical or any other health care advice, diagnosis or treatment. The site and its services, including the information above, are for informational purposes only and are not a substitute for professional medical advice, examination, diagnosis or treatment. Always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to existing treatment. Do not delay seeking and do not disregard medical advice based on information on this site. Cancer Monthly is solely to be used as an informational resource and should never be used to replace contact with your licensed healthcare provider.